Abstract
Gram-positive infections impose a major burden on patients and the healthcare systems globally. The need to treat these infections correctly in an empirical fashion is of paramount importance. Further complicating this changing aetiology is the emergence of resistant strains which are no longer predictably susceptible to standard first-line antimicrobials such as oxacillin or vancomycin. Thus new agents such as linezolid have been developed to assist with initial empirical prescribing in infections where Gram-positive pathogens may be present. The characteristics of linezolid, including spectrum of activity, pharmacodynamic profile, tolerablility and overall efficacy should strengthen confidence when considering initial antimicrobial therapy in patients in risk areas. Future agents also being developed to fight multi-resistant Gram-positive infections include oritavancin, daptomycin and the glycylcyclines; however, these are still in the development phase.
References
Aug 21, 1992·Science·M L Cohen
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J W ChowM J Zervos
Sep 3, 1999·The Journal of Antimicrobial Chemotherapy·R L NicholsB Kreter
Mar 18, 2000·Journal of Chemotherapy·M J Wood
Mar 11, 2000·American Journal of Respiratory and Critical Care Medicine·J FagonF Lilienthal
Mar 16, 2000·Drugs·D I Diekema, R N Jones
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·M J RybakR G Grucz
Sep 15, 2000·The Medical Letter on Drugs and Therapeutics
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J E McGowan
Oct 6, 2000·The Journal of Antimicrobial Chemotherapy·F P Tally, M F DeBruin
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·D L StevensB Hafkin
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D E LowR N Jones
Apr 27, 2001·Lancet·R D GonzalesJ P Quinn
Jun 5, 2001·The Journal of Antimicrobial Chemotherapy·C J HenwoodUNKNOWN Pseudomonas Study Group
Jun 26, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Inf
Nov 23, 2001·Pharmacotherapy·D J Kuter, G S Tillotson
Citations
Jan 27, 2011·PloS One·Irina SinakevitchBrian H Smith
Mar 3, 2004·The Annals of Pharmacotherapy·Jack Brown, Burgess B Freeman
Aug 19, 2005·Expert Review of Anti-infective Therapy·André Bryskier
Mar 16, 2007·Expert Opinion on Emerging Drugs·Emma J Bishop, Benjamin P Howden